[1] T.C Sağlık Bakanlığı, (2018, 5 Eylül), “Türkiye kanser istati̇sti̇kleri̇” [Online], Erişim: https://hsgm.saglik.gov.tr/tr/kanser-istatistikleri.
[2] G. Süss-Fink, “Arene ruthenium complexes as anticancer agents,” Dalton
Transactions, c. 39, sayı 7, ss. 1673–1688, 2010.
[3] B. Rosenbeng, L. Vancamp, J. E. Trosko, and V. H. Mansour, “Response of the testicular capsule to acetylcholine and noradrenaline,” Nature, c. 222, ss. 285–286, 1969.
[4] E. Orhan, A. Garci, and B. Therrien, “Coordination-drive self-assembly of arene ruthenium metalla-rectangles,” Inorganica Chimica Acta, c. 461, ss. 78–83, 2017. [5] W. H. Ang and P. J. Dyson, “Ruthenium-based anticancer drugs: Towards targeted chemotherapy,” European Journal of Inorganic Chemistry, ss. 4003–4018, 2006. [6] S. P. Fricker, “Metal based drugs: From serendipity to design,” Dalton
Transactions, ss. 4903–4917, 2007.
[7] M. Galanski, M. A. Jakupec, and B. K. Keppler, “Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches,” Current Medicinal Chemistry, c. 12, ss. 2075–2094, 2005. [8] C. S. Allardyce and P. J. Dyson, “Ruthenium in medicine: current clinical uses and
future prospects,” Platinum Metals Review, c. 45, sayı 2, ss. 62–69, 2001.
[9] I. Kostova, “Ruthenium complexes as anticancer agents,” Current Medicinal
Chemistry, c. 13, ss. 1085–1107, 2006.
[10] C. S. Allardyce, A. Dorcier, C. Scolaro, and P. J. Dyson, “Development of organometallic (organo-transition metal) pharmaceuticals,” Bioorganometallic
Chemistry, c. 19, ss. 1–10, 2005.
[11] A. A. Hummer, P. Heffeter, W. Berger, M. Filipits, D. Batchelor, G. E. Buechel, M. A. Jakupec, B. K. Keppler, and A. Rompel, “X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active Indazolium trans - [tetrachlorobis(1H- indazole)ruthenate(III)] (KP1019),”
Journal of Medicinal Chemistry, c. 56, ss. 1182, 2013.
[12] G. Tamasi, C. Bernini, G. Corbini, N. F. Owens, L. Messori, F. Scaletti, L. Massai, P. LoGiudice and R. Cini, “Synthesis, spectroscopic and DFT structural characterization of two novel ruthenium (III) oxicam complexes. In vivo evaluation of anti-in fl ammatory and gastric damaging activities,” Journal of
Inorganic Biochemistry, c. 134, ss. 25–35, 2014.
[13] G. Süss-Fink, “Water-soluble arene ruthenium complexes: From serendipity to catalysis and drug design,” Journal of Organometallic Chemistry, c. 751, ss. 2–19, 2014.
[14] B. Therrien, “ChemInform Abstract: Biologically relevant biologically relevant arene ruthenium,” CrystEngComm, c. 17, ss. 484–491, 2015.
52
[15] E. Orhan, A. Garci, and B. Therrien, “Flexible arene ruthenium metalla-prisms,”
Inorganica Chimica Acta, c. 438, ss. 5–9, 2015.
[16] H. Küçükbay, R. Durmaz, E. Orhan, ve S. Günal, “Synthesis and antimicrobial activities of some transition metal benzimidazole complexes,” Farmaco, c. 22, ss. 7376–7382, 2010.
[17] H. Küçükbay, R. Durmaz, E. Orhan, ve S. Günal, “Sysnthesis antibacterial and antifungal activities of electron-rich olefins derived benzimidazole compounds,”
Asian Journal of Chemistry, c. 58, ss. 431–437, 2003.
[18] J. R. Durig, J. Danneman, W. D. Behnke, and E. E. Mercer, “The induction of filamentous growth in Escherichi Coli by ruthenium and palladium complexes,”
Chemico-Biological Interactions, c. 13, ss. 287–294, 1976.
[19] M. J. Clarke, “Oncological implications of the chemistry of ruthenium,” Metal Ions
in Biological Systems, c. 11, ss. 231–283, 1980.
[20] T. J. Kealy and P. L. Pouson, “Theoretical determination of electron density in organic molecules,” Nature, c. 168, ss. 1039–1040, 1951.
[21] G. Wilkinson, M. Rosenblum, M. C. Whiting, and R. B. Woodward, “The structure of oron Bis-Cyclopentadienyl,” Communications To The Edito, c. 74, ss. 2125– 2126, 1952.
[22] G. Wilkinson, “The preparation and some properties of ruthenocene and ruthenicinium salts,” Notes, c. 74, sayı 3, ss. 6146–6147, 1953.
[23] P. Jutzi and G. Reumann, “Cp Chemistry of main-group elements,” Journal of
Dalton Transactions, ss. 2237–2244, 2000.
[24] E. O. Fischer and W. Hafner, “Di-benzol-chrom,” Zeitschrift Für Naturforschg, sayı 10 b, ss. 665–668, 1955.
[25] D. Jones, L. Pratt, and G. Wilkinson, “π-Cyclohexadienyl compounds of manganese, rhenium, iron, and ruthenium,” Journal of the Chemical Society, ss. 4458–4463, 1962.
[26] M. A. Bennett and T. W. Matheson, “A simple pr of bis arene ruthenium cationic complexes, including those containing different arenes,” Journal of Organometallic Chemistry, c. 175, ss. 87–93, 1979.
[27] B. Therrien, “Arene ruthenium complexes in supramolecular chemistry,”
Advances in Inorganic Chemistry, c. 71, ss. 379–401, 2018.
[28] A. K. Singha, D. S. Pandey, Q. Xua, and P. Braunstein, “Recent advances in supramolecular and biological aspects of arene ruthenium (II) complexes,”
Coordination Chemistry Reviews, c. 270–271, ss. 31–56, 2014.
[29] F. Zobi, B. Mood, P. A. Wood, F. P. A. Fabbiani, S. Parsons, and P. J. Sadler, “Tagging (Arene) ruthenium (II) anticancer complexes with fluorescent labels,”
European Journal of Inorganic Chemistry, ss. 2783–2796, 2007.
[30] R. A. Zelonka and M. C. Baird, “Benzene complexes of ruthenium (II),” Canadian Journal of Chemistry, c. 50, ss. 3063–3072, 1972.
[31] M. A. Bennett, T. N. Huang, T. W. Matheson, and A. K. Smith, “(η6- Hexamethylbenzene) ruthenium complexes,” Inorganic Syntheses, c. 21, ss. 74– 78, 1982.
53
[32] D. P. Smith, E. Baralt, B. Morales, M. M. Olmstead, M. F. Maestre, and R. H. Fish, “Bioorganometallic chemistry 1. synthesis, structure, and selecti reactions of a nucleobase and several nucleosides with a (.eta.5-pentamethylcyclopentadienyl) rhodium aqua complex,” Journal of the American Chemical Society, c. 114, ss. 10647, 1992.
[33] P. Annen, S. Schildberg, and W. S. Sheldrick, “(h5-Pentamethylcyclopentadienyl) iridium (III) complexes of purine nucleobases and nucleotides: A comparison with (h6-arene) ruthenium (II) and (h5-pentamethylcyclopentadienyl) rhodium (III) species,” Inorganica Chimica Acta, c. 307, ss. 115, 2000.
[34] H. Piotrowski, G. Hilt, A. Schulz, P. Mayer, K. Polborn, and K. Severin, “Self- assembled organometallic [12] metallacrown-3 complexes holger,” Chemistry
European Journal, c. 7, ss. 3196–3208, 2001.
[35] A. Garci, S. Marti, S. Schürch, and B. Therrien, “Insight into the dynamic ligand exchange process involved in bipyridyl linked arene ruthenium metalla- rectangles,” The Royal Society of Chemistry Advances, c. 4, ss. 8597–8604, 2014. [36] W. H. Ang, Z. Grote, R. Scopelliti, L. Juillerat-Jeanneret, K. Severin, and P. J. Dyson, “Organometallic complexes that interconvert between trimeric and monomeric structures as a function of pH and their effect on human cancer and fibroblast cells,” Journal of Organometallic Chemistry, c. 694, ss. 968–972, 2009. [37] S. Korn and W.S. Sheldrick, “Oligomeric (ղ6-arene) ruthenium (II) complexes of adenine and adenosine with N6, N7 coordination,” Inorganica Chimica Acta, c. 254, ss. 85–91, 1997.
[38] H. Yan, G. Süss-Fink, A. Neels, and H. Stoeckli-Evans, “Mono-, di- and tetra- nuclear p-cymeneruthenium complexes containing oxalato ligands,” Dalton
Transactions, ss. 4345–4350, 1997.
[39] V. Vajpayee, Y. H. Song, M. H. Lee, H. Kim, M. Wang, P. J. Stang, and K. W. Chi, “Self-assembled arene–ruthenium-based rectangles for the selective sensing of multi-carboxylate anions,” Chemistry European Journal, c. 17, ss. 7837–7844, 2011.
[40] T. R. Cook, V. Vajpayee, M. H. Lee, P. J. Stang, and A. K. Chi, “Biomedical and biochemical applications of self-assembled metallacycles and metallacages,”
Accounts Chemical Research, c. 46, ss. 2464, 2013.
[41] A. Mishra, H. Jung, J. W. Park, H. K. Kim, H. Kim, P. J. Stang, and K.-W Chi, “Anticancer activity of self-assembled molecular rectangles via arene−ruthenium acceptors and a new unsymmetrical amide ligand,” Organometallics, c. 31, ss. 3519–3526, 2012.
[42] E. Orhan, A. Garci, T. Riedel, P. J. Dyson, and B. Therrien, “Cytotoxicity of arene ruthenium metalla-rectangles incorporating bis-pyridyl diimide linkers,” Journal
of Organometallic Chemistry, c. 815–816, ss. 53–58, 2016.
[43] V. Vajpayee, Y. H. Song, Y. J. Yang, S. C. Kang, H. Kim, I. S. Kim, M. Wang, P. J. Stang, and K. W. Chi “Coordination-driven self-assembly and anticancer activity of molecular rectangles containing octahedral ruthenium metal centers,”
54
[45] S. Alvarez, M. Pinsky, and D. Avnir, “A continuous chirality analysis of homoleptic hexacoordinated complexes,” European Journal of Inorganic
Chemistry, ss. 1499–1503, 2001.
[46] P. Govindaswamy, G. Süss-Fink, and B. Therrien, “Self-assembled chloro-bridged (Arene) ruthenium metallo-prisms: synthesis and molecular structure of cationic complexes of the type [Ru6(η6-arene)6(µ3-tpt-KN)2(µ-Cl)6]6+ (tpt) 2,4,6- tris(pyridinyl)-1,3,5-triazine),” Organometallics, c. 26, ss. 915–924, 2007.
[47] A. Garci, A. A. Dobrov, T. Riedel, E. Orhan, P. J. Dyson, V. B. Arion, and B. Therrien, “Strategy to optimize the biological activity of arene ruthenium metalla- assemblies,” Organometallics, c. 33, ss. 3813–3822, 2014.
[48] M. A. Furrer, A. Garci, E. D. D. Muro, P. Trouillas, F. Giannini, J. Furrer, C. M. Clavel, P. J. Dyson, G. Süss-Fink and B. Therrien, “Synthesis , Characterisation and In Vitro Anticancer Activity of Hexanuclear Thiolato-Bridged Arene Ruthenium Metalla-Prisms,” Chemistry European Journal, c. 19, ss. 3198–3203, 2013.
[49] R. Langer and D. A. Tirrell, “Designing materials for biology and medicine,”
Nature, c. 428, ss. 487–492, 2004.
[50] N. P. E. Barry, O. Zava, P. J. Dyson, and B. Therrien, “Excellent correlation between drug release and portal size in metalla-cage drug-delivery systems,”
Chemistry European Journal, c. 17, ss. 9669–9677, 2011.
[51] M. Pernot, T. Bastogne, N. P.E. Barry , B. Therrien, G. Koellensperger, S. Hann, V Reshetov and M. Barberi-Heyob, “Systems biology approach for in vivo photodynamic therapy optimization of ruthenium-porphyrin compounds,” Journal
of Photochemistry and Photobiology, c. 117, ss. 80–89, 2012.
[52] B. Therrien, G. Süss-Fink, P. Govindaswamy, A. K. Renfrew, and P. J. Dyson, “The ‘Complex-in-a-Complex’ cations [(acac)2MRu6-(p-iPrC6H4Me)6(tpt)2 (dhbq)3]6+ : A trojan horse for cancer cells,” Angewandte Chemie, c. 47, ss. 3773– 3776, 2008.
[53] J. Mattsson, O. Zava, A. K. Renfrew, Y. Sei, K. Yamaguchi, P. J. Dysonb and B. Therrien, “Drug delivery of lipophilic pyrenyl derivatives by encapsulation in a water soluble metalla-cage,” Dalton Transactions, c. 39, ss. 8248–8255, 2010. [54] A. Pitto-barry, O. Zava, P. J. Dyson, R. Deschenaux, and B. Therrien,
“Enhancement of cytotoxicity by combining pyrenyl-dendrimers and arene ruthenium metallacages,” Inorganic Chemistry, c. 51, ss. 7119–7124, 2012. [55] J. W. Yi, N. P. E. Barry, M. A. Furrer, O. Zava, P. J. Dyson, B. Therrien, and B.
H. Kim, “Delivery of floxuridine derivatives to cancer cells by water-soluble organometallic cages,” Bioconjugate Chemistry, c. 23, ss. 461–471, 2012.
[56] A. Garci, J. Mbakidi, V. Chaleix, V. Sol, E. Orhan, and B. Therrien, “Tunable arene ruthenium metallaprisms to transport, shield, and release porphin in cancer cells,” Organometallics, c. 34, ss. 4138–4146, 2015.
[57] O. Zava, J. Mattsson, B. Therrien, and P. J. Dyson, “Evidence for drug release from a metalla-cage delivery vector following cellular internalisation,” Chemistry
55
[58] F. Schmitt, J. Freudenreich, N. P. E. Barry, L. Juillerat-Jenneret, G. Süss-Fink, and B. Therrien, “Organometallic cages as vehicles for intracellular release of photosensitizers,” Journal of the American Chemical Society, c. 134, ss. 754–757, 2012.
[59] N. P. E. Barry, P. Govindaswamy, J. Furrer, G. Süss-fink, and B. Therrien, “hydroxyquinonato-bridged diruthenium clips,” Inorganic Chemistry Communications, c. 11, ss. 1300–1303, 2008.
[60] F. Schmitt, N. P. E. Barry, L. Juillerat-jeanneret, and B. Therrien, “Efficient photodynamic therapy of cancer using chemotherapeutic porphyrin–ruthenium metalla-cubes,” Bioorganic-Medicinal Chemistry Letters, c. 22, ss. 178–180, 2012. [61] N. P. E. Barry, N. H. A. Karim, R. Vilar, and B. Therrien, “Interactions of ruthenium coordination cubes with DNA,” Dalton Transactions, ss. 10717–10719, 2009.
[62] C. M. Drain and J-M. Lehn, “Self-assembly of square multiporphyrin arrays by metal ion coordination,” Journal of the Chemical Society, Chemical
Communications, ss. 2313–2315, 1994.
[63] A. Weiss, R. H. Berndsen, M. Dubois, C. Müller, R. Schibli, A. W. Griffioen, P. J. Dyson and P. Nowak-Sliwinskaa, “In vivo anti-tumor activity of the organometallic ruthenium (II) arene complex [Ru(ɳ6-p-cymene)Cl2(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas,” Chemical Science, c.
1-3, ss.1-8, 2013.
[64] A. Pitto-Barry, N. P. E. Barry, O. Zava, R. Deschenaux, P. J. Dyson, and B. Therrien, “Double targeting of tumours with pyrenyl-modified dendrimers encapsulated in an arene–ruthenium metallaprism,” Chemistry European Journal, c. 17, ss. 1966–1971, 2011.
[65] M. A. Furrer, F. Schmitt, M. Wiederkehr, L. Juillerat-Jeanneret and B. Therrien, “An international journal of inorganic chemistry,” Dalton Transactions, c. 41, ss. 7201–7211, 2012.
[66] M. Han, R. Michel, B. He, Y. S. Chen, D. Stalke, M. John, and G. H. Clever, “Light-triggered guest uptake and release by a photochromic coordination cage,”
Angewandte Chemie, c. 52, ss. 1319–1323, 2013.
[67] Ü. Ergun, “ONO Ve ONNO tipindeki schiff bazlarının geçiş metalleri komplekslerinin termal bozunma tepkimelerinde kinetik parametrelerinin belirlenmesi ve bazı koordinasyon bağ enerjilerinin hesaplanması,” Doktora tezi, Kimya, Fen Bilimleri Enstitüsü, Ankara Üniversitesi, Ankara, Türkiye, 2009. [68] M. A. Bennett and A. K. Smith, “Arene ruthenium (II) complexes formed by
dehydrogenation of cyclo-hexadienes with ruthenium (III) trichloride,” Dalton Transactions, ss. 233–241, 1974.
[69] H. Yan, G. Süss-fink, A. Neels, and H. Stoeckli-evans, “Mono-, di- and tetra- nuclear p-cymene ruthenium complexes containing oxalato ligands,” Journal of
the Chemical Society, c. 6, ss. 4345–4350, 2000.
[70] N. P. E. Barry and B. Therrien, “Host-guest chemistry in the hexanuclear (arene) ruthenium metalla-prismatic cage [Ru6(p-cymene)6(tpt)2(dhnq)3]6+,” European Journal of Inorganic Chemistry, c. 6, ss. 4695–4700, 2009.
56
[71] H. Küçükbay, R. Durmaz, N. Okuyucu, S. Günal, and C. Kazaz, “Synthesis and antibacterial activities of new bis-benzimidazoles,” Arzneimittel Forschung - Drug
Research, c. 54, sayı 1, ss. 64–68, 2004.
[72] N. Öksüz ve E. Orhan, “Bisbenzimidazol bağlayıcı içeren biyolojik aktif aren rutenyum bileşiğinin sentezi ve termal bozunmasının belirlenmesi,” Düzce
57